Pharmata, cilt.3, sa.4, ss.99-104, 2023 (Hakemli Dergi)
Objective: The combination of the non-steroidal anti-inflammatory drug dexketoprofen trometamol (DXT) and the centrally acting muscle relaxant thiocolchicoside (TH) is used for symptomatic relief in various conditions, with the aim of alleviating associated symptoms. The study
involves the development, validation, and application of the chemometrics-based spectrophotometric method.
Methods: An integral aspect of the investigation is the strategic application of experimental
design techniques for calibration and validation mixtures to facilitate the assessment of factor
effects within complex matrices. In this study, a factorial design was used to prepare calibration
(25 samples) and validation (8 samples) sets comprising mixtures of DXT and TH within their linear
ranges (2.5-25 µg/mL for DXT and 2-16 µg/mL for TH).
Results: Spectra of the acquired mixtures and samples were recorded at wavelengths between
220nm and 460 nm at Δλ=1 nm intervals. Using regression models based on the principal component regression algorithm, the results obtained showed satisfactory performance, with a
recovery rate of ≤98.54% for DXT and ≤98.88% for TH.
Conclusion: These models offer the potential for accurate identification and quantification of DXT
and TH in pharmaceutical preparations
Keywords: Dexketoprofen trometamol, experimental design, PCR, thiocolchicoside